Epsilogen develops immunoglobulin E (IgE) antibodies, specifically targeting solid tumors like ovarian cancer, to enhance treatment efficacy through improved tumor access and potency. Their lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, demonstrating safety and early signs of clinical activity in patients with folate receptor alpha positive cancers.
Funding
$66.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors present a significant challenge in oncology due to limited antibody penetration, suboptimal immune cell activation, and short tissue half-life of conventional IgG-based therapies. These factors contribute to reduced treatment efficacy and poor patient outcomes.
Solution
Epsilogen is developing immunoglobulin E (IgE) antibodies as a novel therapeutic modality for solid tumors, leveraging IgE's enhanced potency, improved tumor access, and extended tissue half-life compared to traditional IgG antibodies. Their lead candidate, MOv18 IgE, targets folate receptor alpha positive cancers, such as ovarian cancer, and has demonstrated safety and early clinical activity in Phase I trials. Epsilogen's proprietary IgEG platform further expands the therapeutic potential of IgE by creating fusion antibodies that combine the benefits of both IgE and IgG isotypes. This approach aims to overcome the limitations of existing cancer immunotherapies and improve treatment outcomes for patients with solid tumors.
Target Audience
The primary target audience includes patients with solid tumors, particularly those expressing folate receptor alpha, and pharmaceutical companies seeking innovative cancer immunotherapy approaches.
Features
- MOv18 IgE: A first-in-class therapeutic IgE antibody targeting folate receptor alpha, currently in clinical development.
- IgEG Platform: A proprietary technology for generating IgE-IgG fusion antibodies with enhanced functionality.
- Enhanced tumor penetration: IgE antibodies exhibit superior diffusion into solid tumors compared to IgG antibodies.
- Increased potency: IgE antibodies demonstrate greater cytotoxic activity against cancer cells.
- Extended tissue half-life: IgE antibodies persist longer in tumor tissues, enabling sustained therapeutic effects.
- Novel pipeline of anti-cancer IgE and IgE-derivative antibodies with enhanced functionality.